Jagsonpal Pharmaceuticals Limited has made the audio recording of its Q4 FY26 earnings conference call available on the company website. The jagsonpal pharmaceuticals informed both BSE and NSE about the availability of this recording following the completion of the scheduled investor engagement activity on April 28, 2026.

Conference Call Completion

The earnings conference call was successfully conducted as scheduled with the following details:

Audio Recording Availability

In continuation to the earlier intimation dated April 22, 2026, the company has announced that the complete audio recording of the Q4 FY26 earnings conference call is now accessible to stakeholders:

Regulatory Compliance

The company has notified stock exchanges about the audio recording availability pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Pratham Rawal digitally signed the official communication on April 28, 2026, at 17:54:14 +05'30'.

Investor Access

The audio recording provides comprehensive coverage of the Q4 FY26 financial results discussion that took place during the scheduled conference call. Investors, analysts, and other stakeholders who were unable to participate in the live session can now access the complete proceedings through the company's official website under the investor relations section.

Jagsonpal Pharmaceuticals Limited has announced the successful allotment of 1,76,900 equity shares under its Employee Stock Option Plan 2022 (JPL ESOP 2022) to eligible employees. The allotment was completed on April 13, 2026, following the exercise of vested options by company employees.

Share Capital Enhancement

The allotment has resulted in a significant increase in the company's paid-up share capital. The following table shows the capital structure before and after the allotment:

Exercise Price Structure

The ESOP shares were allotted at three different exercise price levels, reflecting the varying grant dates and market conditions at the time of option grants:

Regulatory Compliance and Share Details

The company has fulfilled all regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The newly allotted shares carry distinctive numbers from 6,69,62,251 to 6,71,39,150 and will be issued in demat form.

Key regulatory aspects include:

• The shares rank pari passu with existing equity shares in all respects
• No lock-in period applies to the allotted shares
• The company's shares are listed on BSE Limited and National Stock Exchange of India Limited
• Original ESOP filing was completed in July 2022 with both exchanges

Corporate Structure

Jagsonpal Pharmaceuticals Limited, incorporated in 1978, operates from its corporate office in Gurugram, Haryana, with its registered office located in New Delhi. The company maintains additional operational presence in Mumbai, Maharashtra. The allotment was approved by the Nomination and Remuneration Committee and executed by Company Secretary Pratham Rawal.

The successful completion of this ESOP allotment demonstrates the company's commitment to employee participation in its growth story while strengthening its equity base through internal capital generation.